COMPARISON OF EFFECTIVENESS OF TOLTERODINE, TADALAFIL IN TREATMENT OF DOUBLE J STENT RELATED LOWER URINARY SYMPTOMS
Objectives: The purpose of this study was to evaluate the effectiveness of Tolterodine, Tadalafil in relieving ureteral stent related symptoms.
Material and Methods: In this prospective 71 patients who underwent DJ stenting were randomized in 3 groups. They were given USSQ and were asked to come with completed USSQ at 1st week and 3rd week before removal of DJ stent. The statistical significant difference among groups was determined by paired T-test and one-way ANOVA test.Results and Conclusion: Tadalafil is as effective as Tolterodine alone in relieving urinary symptom but more effective in relieving sexual symptoms.
Agarwal A, Dhiraaj S, Singhal V, Kapoor R, and Tandon M. (2006). “Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study,” British Journal of Anaesthesia, Vol.96(3), pp.377-380.
Beddingfield R, Pedro RN, Hinck B, Kreidberg C, Feia K, and Monga M. (2009). “Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study”, J Urol, Vol.181, pp.170-176.
Blake-James BT, Rashidian A, Ikeda Y, and Emberton M. (2007). “The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis”, BJU Int., Vol.99, pp.85-96, discussed in Urol, (2009), Vol.56, pp.534-541.
Byrne RR, Auge BK, Kourambas J, Munver R, Delvecchio F, and Preminger GM. (2002). “Routine ureteral stenting is not necessary after ureteroscopy and ureteropyeloscopy: a randomized trial,” Journal of Endourology, Vol.16(1), pp.9-13.
Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, and Guan Z. (2009). “Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers”, Eur Urol, Vol.56, pp.534-541.
Chew BH, Knudsen BE, and Denstedt JD. (2004). “The use of stents in contemporary urology”, Curr Opin Urol, Vol.14, pp.111-115.
Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, and D’Armiento M. (2008). “Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study,” Journal of Endourology, Vol.22(4), pp.651-656.
Dellis AE, Keeley FX, Manolas V, and Skolarikos AA. (2014). “Role of 𝛼-blockers in the treatment of stent-related symptoms: a prospective randomized control study,” Urology, Vol.83(1), pp.56-61.
Hajebrahimi S, Farshi A, Jabbari A, Bazargani HS, Babaei H, and Mostafaie H. (2015). “Does tadalafil alleviate ureteral stent related symptoms? A randomized controlled trial,” European Urology Supplements, Vol.14(2), p.e1080.
Haleblian G, Kijvikai K, de la Rosette J, and Preminger G. (2008). “Ureteral stenting and urinary stone management: a systematic review”, J Urol, Vol.179, pp.424-430.
Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley Jr FX, and Timoney AG. (2003). “Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure,” The Journal of Urology, Vol.169(3), pp.1060-1064.
Joshi HB, Okeke A, Newns N, Keeley Jr FX, and Timoney AG. (2002). “Characterization of urinary symptoms in patients with ureteral stents,” Urology, Vol.59(4), pp.511-516.
Joshi HB, Stainthorpe A, MacDonagh RP, Keeley Jr FX, and Timoney AG. (2003). “Indwelling ureteral stents: evaluation of symptoms, quality of life and utility,” Journal of Urology, Vol.169(3), pp.1065-1069.
Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, and Guan Z. (2006). “Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial”, JAMA, Vol.296, pp.2319-2328, Erratum in: JAMA. (2007), Vol.298, p.1864.
Lamb AD, Vowler SL, Johnston R, Dunn N, and Wiseman OJ. (2011). “Meta-analysis showing the beneficial effect of 𝛼-blockers on ureteric stent discomfort,” BJU International, Vol.108(11), pp.1894-1902.
Lim KT, Kim YT, Lee TY, and Park SY. (2011). “Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent related discomforts,” Korean Journal of Urology, Vol.52(7), pp.485-488.
Miyaoka R, and Monga M. (2009). “Ureteral stent discomfort: Etiology and management”, Indian J Urol, Vol.25, pp.455-460.
Mokhtari G, Shakiba M, Ghodsi S, Farzan A, Heidari Nejad S, and Esmaeili S. (2011). “Effect of terazosin on lower urinary tract symptoms and pain due to double-J stent: a double-blind placebocontrolled randomized clinical trial”, Urol Int, Vol.87, pp.19-22.
Park SC, Jung SW, Lee JW, and Rim JS. (2009). “The effects of tolterodine extended release and alfuzosin for the treatment of double-J stent-related symptoms,” Journal of Endourology, Vol.23(11), pp.1913-1917.
Rane A, Saleemi A, Cahill D, Sriprasad S, Shrotri N, and Tiptaft R. (2001). “Have stent-related symptoms anything to do with placement technique?,” Journal of Endourology, Vol.15(7), pp.741-745.
Thomas R. (1993). “Indwelling ureteral stents: impact of material and shape on patient comfort,” Journal of Endourology, Vol.7(2), pp.137-140.
Yakoubi R, Lemdani M, Monga M, Villers A, and Koenig P. (2011). “Is there a role for 𝛼-blockers in ureteral stent related symptoms? A systematic review and meta-analysis,” Journal of Urology, Vol.186(3), pp.928-934.
- There are currently no refbacks.
Send mail to firstname.lastname@example.org with questions or comments about this web site.
International Journal of Surgery and Surgical Sciences, All rights reserved.